dm+d
82573000
Articles
Lidocaine products: information for supporting intrathecal risk assessment
11 August 2022Lidocaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Administration of ceftriaxone injection (with lidocaine) by intramuscular (IM) injection for the treatment of uncomplicated Neisseria gonorrhoeae infection: PGD template
5 October 2021A PGD template developed by SPS and the British Association of Sexual Health and HIV (BASHH) and British Association of HIV (BHIVA).
Administration of lidocaine injection to facilitate insertion and/or removal of subdermal etonogestrel (e.g. Nexplanon®) implant: PGD template
4 October 2021A PGD template developed by SPS and the Faculty of Sexual and Reproductive Health (FSRH).
Safety in Lactation: Drugs for rectal and anal disorders
21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Rectal glyceryl nitrate and diltiazem (unlicensed)…
Safety in Lactation: Local anaesthetic eye preparations
15 October 2020Local anaesthetics for ophthalmic use have limited systemic absorption in the mother, and pose negligible risk to a breastfed infant. Systemic absorption from eye drops…
Lactation Safety Information
Intravenous as anti-arrhythmic
Intravenous
as anti-arrhythmic
-
Small amounts in breast milk
Moderate published evidence of use in breastfeeding
Minimal absorption from the infant’s GI tract
Used in full-term neonates from birth
30 July 2020
For local anaesthesia
For local anaesthesia
Limited published evidence of safety
This entry applies to all uses (infiltration, regional and surface anaesthesia and nerve blocks) and formulations (injection/topical) of lidocaine for local anaesthesia, including injections with adrenaline
Small amounts in breast milk and minimal absorption from the infant’s GI tract
30 July 2020
For ophthalmic use
For ophthalmic use
Only available in combination with fluorescein for which there are no additional risks
30 July 2020
Ointment/spray for orophayngeal use
Ointment/spray for orophayngeal use
30 July 2020
Rectal
Rectal
-
Topical/rectal use for short periods in combination with a corticosteroid considered to present minimal risk to breastfed infant
30 July 2020
New Medicines
LidbreeTopical anaesthesia for moderate acute pain during cervical and intrauterine procedures, in adults and adolescents from 15 years of age
Information
Lidbree
New formulation
Gedeon Richter
Not Known
Development and Regulatory status
Licensed but not launched
None
None
Sep 22UK launch of Lidbree is now planned for November 2022 and will be available by private prescription only. Price for 1 pack will be £22 [7].
Feb 22UK launch of Lidbree is planned for July 2022, but it will be available by private prescription only [6].
Sep 21Company is now planning UK launch [5].
Sep 20No plans to launch in the UK anytime soon [4].
Jul 20Lidocaine (Lidbree) 42 mg/mL intrauterine gel was approved in the UK for topical anaesthesia for moderate acute pain during cervical and intrauterine procedures, in adults and adolescents from 15 years of age [1].
Category
Lidocaine is a local anaesthetic of the amide type. Lidocaine reversibly stabilises neuronal membranes and prevents initiation and conduction of nerve impulses, thus providing local anaesthesia [1].
Some women feel no or only mild pain during a hysteroscopy, but for others the pain can be severe [2]. Cervical biopsy and cervical curettage are associated with visual analogue scale (VAS) pain scores ranging from four to six on a 10-point scale. Endometrial biopsies done have VAS scores of five to seven. Pain with intrauterine device insertion varies from two to seven, and pain scores during laminaria insertions with paracervical block range from five to seven [3].
Topical anaesthesia for moderate acute pain during cervical and intrauterine procedures, in adults and adolescents from 15 years of age
Intrauterine